Teriflunomide modulates the PD-1/PD-L1 axis and enhances antitumor immunity in colorectal cancer

Related articles

1. Tumor Treating Fields (TTFields) sensitize anti-PD1-resistant lung tumors to PD1 blockade and remodel myeloid and lymphoid states

   This article has 10 authors:

   1. Yun Hu
   2. Fatemeh Maspourour
   3. Qi Wang
   4. Ailing Huang
   5. Hampartsoum Barsoumian
   6. Zahid Rafiq
   7. Ashley Hoffman
   8. Denton Robinson
   9. Jing Wang
   10. James W. Welsh

2. L1CAMxCD3 bispecific antibodies exert potent anti-tumor effects in preclinical pancreatic cancer models considering the complex tumor stroma

   This article has 19 authors:

   1. Anna Maxi Wandmacher
   2. Annika Brauer
   3. Charlotte Kayser
   4. Caj Stach
   5. Jakob Werner
   6. Silje Beckinger
   7. Tina Daunke
   8. Leon Baumann
   9. Benjamin Heckelmann
   10. Ashinikumar Hidam
   11. Olha Lapshyna
   12. Daniela Wesch
   13. Anne-Sophie Mehdorn
   14. Christoph Röcken
   15. Rüdiger Braun
   16. Flavio Mehli
   17. Anne Schmidt
   18. Gunther Spohn
   19. Susanne Sebens

3. The coumarin derivative X6632 is a pan-ID protein inhibitor that suppresses tumor growth by targeting cancer cells and the tumor-associated microvasculature

   This article has 19 authors:

   1. Lea S. Götz
   2. Abhilash Deo
   3. Sandra D. Scherer
   4. Luigi D’Antonio
   5. Hanna T. Weber
   6. Georg Sedlmeier
   7. Landy P. Torre Flores
   8. Ulrike Kaiser
   9. Elian Far
   10. Ziv Raviv
   11. Wilko Thiele
   12. Sonja Thaler
   13. Nicole Jung
   14. Stefan Bräse
   15. Caroline S. Hill
   16. Alana L. Welm
   17. Yuval Shaked
   18. Boyan K. Garvalov
   19. Jonathan P. Sleeman